11 April 2024 - Commercialization partner Teva markets FYB201 in Canada under the trademark Ranopto and in Switzerland under the trademark Ranivisio.

Formycon and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. The launch follows the marketing authorization granted by Health Canada under the trademark Ranopto and Swissmedic under the trademark Ranivisio.

Read Formycon press release